Preliminary Report of Extracorporeal Blood Purification Therapy in Patients Receiving LVAD: Cytosorb or Jafron HA330

April 4, 2024 No Comments

This study investigates the effects of extracorporeal blood purification therapy using Cytosorb and Jafron HA330 in patients undergoing Left Ventricular Assist Device (LVAD) implantation, aimed at mitigating immune dysregulation and infectious complications by reducing proinflammatory cytokine levels. Data from 15 patients receiving HeartMate 3™ LVADs were analyzed, with groups assigned to Cytosorb therapy, Jafron HA330, or control (usual care without filters). Results indicated that despite LVAD implantation increasing levels of various inflammatory markers, neither Cytosorb nor Jafron therapies had a significant impact on these markers, in-hospital mortality, or overall survival. The study suggests the need for larger, prospective studies to explore the potential benefits of hemoadsorption therapies in improving outcomes for LVAD patients.

Improving ECMO Therapy: Monitoring Oxygenator Functionality and Identifying Key Indicators, Factors, and Considerations for Changeout

April 4, 2024 No Comments

This article reviews the crucial aspects of determining the optimal timing for extracorporeal membrane oxygenation (ECMO) circuit change-outs to enhance patient outcomes in severe cardiopulmonary failure management. It emphasizes the significance of monitoring coagulation parameters, gas exchange, fibrinogen levels, blood gases, plasma-free hemoglobin, D-dimers, platelet function, flows, pressures, and anticoagulation strategy. The article highlights thrombosis within the membrane oxygenator as a major concern and underlines the importance of a multidisciplinary team and thorough preparation in the change-out process, advocating for standardized protocols and personalized anticoagulation approaches to optimize ECMO therapy.